WallStreetZenWallStreetZen

NASDAQ: CBAY
Cymabay Therapeutics Inc Stock

$8.55+0.02 (+0.23%)
Updated Feb 3, 2023
CBAY Price
$8.55
Fair Value Price
$8.90
Market Cap
$724.02M
52 Week Low
$1.67
52 Week High
$8.75
P/E
-6.79x
P/B
12.03x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$105.91M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.65
Operating Cash Flow
-$80M
Beta
0.88
Next Earnings
Mar 15, 2023
Ex-Dividend
N/A
Next Dividend
N/A

CBAY Overview

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CBAY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CBAY ($8.55) is undervalued by 3.93% relative to our estimate of its Fair Value price of $8.90 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CBAY ($8.55) is not significantly undervalued (3.93%) relative to our estimate of its Fair Value price of $8.90 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CBAY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CBAY due diligence checks available for Premium users.

Be the first to know about important CBAY news, forecast changes, insider trades & much more!

CBAY News

Valuation

CBAY fair value

Fair Value of CBAY stock based on Discounted Cash Flow (DCF)
Price
$8.55
Fair Value
$8.90
Undervalued by
3.93%
CBAY ($8.55) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CBAY ($8.55) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CBAY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CBAY price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-6.79x
Industry
10.7x
Market
15.09x

CBAY price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
12.03x
Industry
5.11x
CBAY is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CBAY's financial health

Profit margin

Revenue
$0.0
Net Income
-$24.5M
Profit Margin
0%
CBAY's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$159.2M
Liabilities
$99.1M
Debt to equity
1.65
CBAY's short-term assets ($155.12M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CBAY's short-term assets ($155.12M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CBAY's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CBAY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$17.5M
Investing
-$4.5M
Financing
$9.0k
CBAY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CBAY vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CBAY$724.02M+0.23%-6.79x12.03x
DYN$729.78M-0.92%-3.99x2.92x
TBPH$717.45M-0.47%0.94x1.49x
ANAB$732.97M-3.30%-5.34x2.64x
MRUS$732.97M-1.49%-11.07x2.45x

Cymabay Therapeutics Stock FAQ

What is Cymabay Therapeutics's quote symbol?

NASDAQ: CBAY) Cymabay Therapeutics trades on the NASDAQ under the ticker symbol CBAY. Cymabay Therapeutics stock quotes can also be displayed as NASDAQ: CBAY.

If you're new to stock investing, here's how to buy Cymabay Therapeutics stock.

What is the 52 week high and low for Cymabay Therapeutics (NASDAQ: CBAY)?

(NASDAQ: CBAY) Cymabay Therapeutics's 52-week high was $8.75, and its 52-week low was $1.67. It is currently -2.29% from its 52-week high and 411.98% from its 52-week low.

How much is Cymabay Therapeutics stock worth today?

(NASDAQ: CBAY) Cymabay Therapeutics currently has 84,681,063 outstanding shares. With Cymabay Therapeutics stock trading at $8.55 per share, the total value of Cymabay Therapeutics stock (market capitalization) is $724.02M.

Cymabay Therapeutics stock was originally listed at a price of $9.00 in Feb 3, 2014. If you had invested in Cymabay Therapeutics stock at $9.00, your return over the last 9 years would have been -5%, for an annualized return of -0.57% (not including any dividends or dividend reinvestments).

How much is Cymabay Therapeutics's stock price per share?

(NASDAQ: CBAY) Cymabay Therapeutics stock price per share is $8.55 today (as of Feb 3, 2023).

What is Cymabay Therapeutics's Market Cap?

(NASDAQ: CBAY) Cymabay Therapeutics's market cap is $724.02M, as of Feb 6, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Cymabay Therapeutics's market cap is calculated by multiplying CBAY's current stock price of $8.55 by CBAY's total outstanding shares of 84,681,063.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.